Body Vision Medical, a leader in AI-powered intraoperative imaging, is pleased to announce that its LungVision advanced imaging platform has received Pre-Market Approval from Singapore's Health Sciences Authority (HSA). This clearance enables full commercialization of LungVision in Singapore and represents a significant milestone in the company's ongoing mission to improve early and accurate diagnosis of lung cancer worldwide.
Lung cancer is a significant health concern in Singapore, ranking as the second most common cancer in men and the third most common in women. Over a five-year period (2018-2022), approximately 9,000 cases were diagnosed. According to the Singapore Cancer Registry, most patients are diagnosed at a late stage, reducing the effectiveness of treatment and survival rates. Improving early diagnosis with advanced imaging technology can have a meaningful impact on patient outcomes.
“Receiving HSA's Pre-Market Approval is an important milestone for physicians and patients in Singapore,” said Benny Krauz, Vice President of Regulatory and Quality at Body Vision Medical. “Physicians will now be able to improve the success of their diagnostic bronchoscopy procedures with real-time three-dimensional imaging, which can lead to a meaningful stage shift in lung cancer diagnostics.”
LungVision transforms any standard two-dimensional fluoroscopic imaging system into an AI-powered 3D imaging system, giving physicians real-time navigation and enhanced visualization to perform more precise bronchoscopic biopsies. The technology supports earlier and more accurate diagnoses of pulmonary nodules-helping improve patient outcomes while keeping procedural costs low.
“Bringing LungVision to Singapore represents an important step forward in enhancing diagnostic accuracy for pulmonary care,” said Daniel Soh, Managing Director for Scanmed Technology. “This platform aligns with our mission to offer high-quality, innovative solutions that improve patient care. LungVision's ability to enhance early detection and biopsy accuracy is an important advancement for pulmonary care in the region.”
For more information about LungVision and its availability in Singapore, please visithttps://scanmed.com.sg or contact Daniel Soh at dsoh@scanmed.com.sg
About Body Vision Medical
Body Vision Medical believes in saving lives through the globalization of innovative medical technology. LungVision provides AI-powered real-time image guidance to address the clinical need for early, definitive lung cancer diagnosis and to enable effective treatment of lung lesions via minimally invasive procedures.
Visitbodyvisionmedical.com to learn more and connect with us on LinkedIn.
About Scanmed Technology
Scanmed Technology PTE LTD is a leading medical solutions provider in Singapore, focused on bringing innovative healthcare technologies to the Singapore market. With deep industry experience and a commitment to clinical excellence, Scanmed partners with global innovators to deliver impactful solutions to healthcare professionals.
Contact:
Mike Hostetler+1.651.366.9584info@bodyvisionmedical.com
https://c212.net/c/img/favicon.png?sn=NY40112&sd=2025-08-05
View original content:https://www.prnewswire.com/news-releases/body-vision-medical-receives-pre-market-approval-for-lungvision-in-singapore-advancing-ai-powered-imaging-for-early-lung-cancer-diagnosis-302516652.html
SOURCE Body Vision Medical
https://rt.newswire.ca/rt.gif?NewsItemId=NY40112&Transmission_Id=202508050805PR_NEWS_USPR_____NY40112&DateId=20250805